Vorasidenib is being integrated in the real-world setting for the treatment of patients with IDH-mutated glioma.
Spencer Feldman
Advertisement
Articles by Spencer Feldman
The SKYSCRAPER-14 trial did not show a PFS benefit with tiragolumab plus atezolizumab and bevacizumab in untreated HCC, missing its coprimary end point.
Elacestrant increased real-world TTNT for patients with ESR1-mutant HR-positive/HER2-negative breast cancer vs PFS from the phase 3 EMERALD trial.
ctDNA was most frequently detected within 6 months post-treatment in patients with TNBC, aligning with the early recurrence pattern characteristic of the disease.
A lower dose of pembrolizumab may be as effective as the standard dose for treating stage IV non-small cell lung cancer.
Advertisement
Latest Updated Articles
Recurrence-Free Interval Is Longer With Low ctDNA Levels at Baseline in TNBCPublished: December 13th 2024 | Updated:
Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast CancerPublished: December 15th 2024 | Updated:
Low-Dose Pembrolizumab May Prove Equal Efficacy as a Standard Dose for Stage IV NSCLCPublished: September 14th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5